Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
<jats:title>Abstract</jats:title><jats:p>Drug resistance and a dire lack of transmission-blocking antimalarials hamper malaria elimination. Here, we present the pantothenamide MMV693183 as a first-in-class acetyl-CoA synthetase (AcAS) inhibitor to enter preclinical development. Our...
Main Author: | Niles, Jacquin |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biological Engineering |
Format: | Article |
Language: | English |
Published: |
Springer Science and Business Media LLC
2023
|
Online Access: | https://hdl.handle.net/1721.1/147889 |
Similar Items
-
Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy
by: Niles, Jacquin
Published: (2023) -
Identification and structural validation of purine nucleoside phosphorylase from Plasmodium falciparum as a target of MMV000848
by: Chung, Zara, et al.
Published: (2024) -
Parasite proteins targeted by the medicines for malaria ventures (MMV) malaria box: identification, functional and structural validation
by: Chung, Zara Shi Ying
Published: (2024) -
Genetic validation of PfFKBP35 as an antimalarial drug target
by: Thommen, Basil T., et al.
Published: (2024) -
Prioritization of Molecular Targets for Antimalarial Drug Discovery
by: Forte, Barbara, et al.
Published: (2023)